Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00326339 · ClinicalTrials.gov registry record · Phase 2
Treatment of Arthritis With Syk Kinase Inhibition (TASKI-1)
A Phase 2 study of Rheumatoid Arthritis, sponsored by Rigel Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 189
- Enrollment target
- 20
- Study locations
NCT00326339 is a Phase 2 study of Rheumatoid Arthritis that has completed, run by Rigel Pharmaceuticals. The registered enrollment target is 189 participants, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (96% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT00326339, a Phase 2 study of Rheumatoid Arthritis, has completed, sponsored by Rigel Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 189 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase II, multicenter, randomized, double-blind, placebo-controlled, ascending dose, dose ranging study to evaluate up to three doses of R935788 (50 mg bid, 100 mg bid and 150 mg bid). Approximately 180 patients who have had rheumatoid arthritis for a minimum of 12 months and who have been receiving a weekly methotrexate (MTX) dose for a minimum of 6 months will be enrolled into the study.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG R788
Study Locations (20)
Florida
- DMI research - Ocala
- Renstar Medical Research - Ocala
- Arthritis & Osteoporosis Treatment Center - Orange Park
- Arthritis Associates Inc. - Orlando
- Arthritis Research of Florida, Inc. - Palm Harbor
- Arthritis Research of Florida - Palm Harbor
- Lovelace Scientific Resources - Sarasota
- The Center for Arthritis and Rheumatic Diseas - South Miami
Pennsylvania
- East Penn Rheumatology Associates - Bethlehem
- Altoona Ctr. for Clinical Research - Duncansville
California
- Pacific Arthritis Center Medical Group - Santa Maria
Idaho
- Coeur d'Alene Arthritis Clinical Trials - Coeur d'Alene
Illinois
- The Arthritis Center - Springfield
Indiana
- MMG Clinical Research - South Bend
Massachusetts
- Phase III Clinical Research - Fall River
Michigan
- Michigan Arthritis Research Center - Brighton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 189 participants |
| Start Date | 2006-08 |
| Est. Completion | 2007-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00326339
The ClinicalTrials.gov registry entry for NCT00326339 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 189 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (96% lower). The listed sponsor is Rigel Pharmaceuticals, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00326339 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Florida, Pennsylvania, California.
Frequently Asked Questions
What is clinical trial NCT00326339 about?
NCT00326339 is a clinical study titled "Treatment of Arthritis With Syk Kinase Inhibition (TASKI-1)". This is a Phase II, multicenter, randomized, double-blind, placebo-controlled, ascending dose, dose ranging study to evaluate up to three doses of R935788 (50 mg bid, 100 mg bid and 150 mg bid). Approximately 180 patients who have had rheumatoid arthritis for a minimum of 12 months and who have been...
What is the current status of trial NCT00326339?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 189 participants. The study started on 2006-08. Estimated completion is 2007-12.
What conditions does trial NCT00326339 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis.
What interventions are being tested in trial NCT00326339?
The interventions under investigation include: Placebo (DRUG), R788 (DRUG).
Who is sponsoring clinical trial NCT00326339?
This trial is sponsored by Rigel Pharmaceuticals, which has 22 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00326339 being conducted?
This trial has 20 study locations across California, Florida, Idaho, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rheumatoid Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of SPY072 in Rheumatic Disease
RECRUITING · Phase 2
-
Dynamic Treatment Regiments for Glucocorticoid Tapering
RECRUITING · Phase 2
-
A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis
RECRUITING · Phase 2
-
A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)
RECRUITING · Phase 2
-
An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.